Immunethep

Executive Summary

Immunethep is a Portuguese biotechnology company founded in 2014, dedicated to developing innovative immunotherapies that harness the immune system to combat bacterial infections. The company's proprietary immunomodulatory platform enables the creation of both preventive and therapeutic multivalent immunotherapies, specifically targeting antimicrobial resistance (AMR) — a growing global health threat. By focusing on boosting the natural ability of the immune system to control infections, Immunethep aims to provide novel solutions where traditional antibiotics are failing. The company's approach is based on a deep understanding of immunomodulation, positioning it as a promising player in the biologics and vaccines space.

Upcoming Catalysts (preview)

• Q3 2026Series A or Major Funding Round60% success
• Q1 2027Preclinical Proof-of-Concept Data for Lead Candidate50% success
• Q4 2026Strategic Partnership or Licensing Deal40% success